China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company's wholly-owned subsidiary Renhuang Pharmaceutial Limited has established a key research laboratory ("the laboratory") in cooperation with Key Laboratory of Forest Plant Ecology (KLP), which is sponsored by Ministry of Education and supported by Northeastern Forest University.
The primary purpose of the key research laboratory is to explore advanced technologies, including the cultivation of bio-active substance technology and environmentally friendly multi-level biological use of technology. The laboratory will apply such advanced techniques to improve and enhance the manufacturing process of China Botanic's fine-processed products such as Siberian Ginseng Lyophilized Syringin Powder and Total Flavonoids capsules. KLP and China Botanic aim to add value to all processes, including planting, collection, processing, research and development, and production. The cooperation with KLP will allow China Botanic to share its research resources and personnel with KLP, which will continue to provide research ideas and opportunities to the Company.
"We are pleased to enter into research cooperation with KLP, a leading plant research laboratory," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We believe the setting up of a key research laboratory will be beneficial to both China Botanic and KLP. This reflects on our effort to provide our customers with excellent products. We will continue to strive to collaborate with similar institutions to deliver advanced products to our customers."
A bout the Key Laboratory of Forest Plant Ecology (KLP)
The key Laboratory of Forest Plant Ecology (KLP) was formed in 1992. It is sponsored by Ministry of Education of China and is supported by Northeast Forestry University. In its first decade, KLP's activity centered on forest plant research fields of Botany, Ecology and Molecular Biology such as Synecology, Molecular Ecology and Calculation Ecology. In recent years, its main focus is on Forest vegetation Ecological Conservation and Biology Resources Ecological Use. Since 2000, it has undertaken a total of 92 research projects including 22 national research projects, published 220 academic papers and obtained 18 independent intellectual property rights.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management ' s beliefs, assumptions and expectations of the Company ' s future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company ' s ability to manage expansion of its operations effectively, and other factors detailed in the Company ' s annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.